- Home
- FURY vs SLGL Comparison
FURY vs SLGL Comparison
Compare FURY & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- SLGL
- Stock Information
- Founded
- FURY 2008
- SLGL 1997
- Country
- FURY Canada
- SLGL Israel
- Employees
- FURY N/A
- SLGL N/A
- Industry
- FURY Precious Metals
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- FURY Basic Materials
- SLGL Health Care
- Exchange
- FURY Nasdaq
- SLGL Nasdaq
- Market Cap
- FURY 84.1M
- SLGL 69.1M
- IPO Year
- FURY N/A
- SLGL 2018
- Fundamental
- Price
- FURY $0.62
- SLGL $40.01
- Analyst Decision
- FURY Strong Buy
- SLGL
- Analyst Count
- FURY 2
- SLGL 0
- Target Price
- FURY $1.40
- SLGL N/A
- AVG Volume (30 Days)
- FURY 592.6K
- SLGL 21.2K
- Earning Date
- FURY 11-11-2025
- SLGL 11-14-2025
- Dividend Yield
- FURY N/A
- SLGL N/A
- EPS Growth
- FURY N/A
- SLGL N/A
- EPS
- FURY N/A
- SLGL N/A
- Revenue
- FURY N/A
- SLGL $23,931,000.00
- Revenue This Year
- FURY N/A
- SLGL N/A
- Revenue Next Year
- FURY N/A
- SLGL $31.17
- P/E Ratio
- FURY N/A
- SLGL N/A
- Revenue Growth
- FURY N/A
- SLGL 264.86
- 52 Week Low
- FURY $0.35
- SLGL $4.01
- 52 Week High
- FURY $0.73
- SLGL $52.26
- Technical
- Relative Strength Index (RSI)
- FURY 48.51
- SLGL 74.00
- Support Level
- FURY $0.61
- SLGL $27.00
- Resistance Level
- FURY $0.68
- SLGL $52.26
- Average True Range (ATR)
- FURY 0.04
- SLGL 4.40
- MACD
- FURY -0.01
- SLGL 0.95
- Stochastic Oscillator
- FURY 13.28
- SLGL 57.87
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.